Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology.1-4 This combination helps identify if a patient is safe for active surveillance (AS) and how refinement of AS intensity can be personalized.4-8 This new paradigm in patient care builds upon technology from PATHOMIQ AI, a digital pathology AI platform company.